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Animal  models  for  Duchenne  muscular  dystrophy 
(DMD)  have  species  limitations  related  to  assessing 
function, immune response, and distribution of micro- 
or mini-dystrophins. Nonhuman primates (NHPs) pro-
vide the ideal model to optimize vector delivery across 
a vascular barrier and provide accurate dose estimates 
for widespread transduction. To address vascular deliv-
ery and dosing in rhesus macaques, we have generated 
a  fusion  construct  that  encodes  an  eight  amino-acid 
FLAG epitope at the C-terminus of micro-dystrophin to 
facilitate translational studies targeting DMD. Intramus-
cular (IM) injection of AAV8.MCK.micro-dys.FLAG in the 
tibialis anterior (TA) of macaques demonstrated robust 
gene  expression,  with  muscle  transduction  (50–79%) 
persisting  for  up  to  5  months.  Success  by  IM  injec-
tion was followed by targeted vascular delivery studies 
using a fluoroscopy-guided catheter threaded through 
the  femoral  artery.  Three  months  after  gene  transfer, 
>80% of muscle fibers showed gene expression in the 
targeted muscle. No cellular immune response to AAV8 
capsid, micro-dystrophin, or the FLAG tag was detected 
by  interferon-γ  (IFN-γ)  enzyme-linked  immunosorbent 
spot (ELISpot) at any time point with either route. In 
summary, an epitope-tagged micro-dystrophin cassette 
enhances the ability to evaluate site-specific localization 
and distribution of gene expression in the NHP in prepa-
ration for vascular delivery clinical trials.
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IntroductIon
Duchenne muscular dystrophy (DMD), inherited as an X-linked 
recessive  disorder  with  monogenic  mutations,  is  the  most 
common  devastating  muscle  disease  of  childhood.  Potential 
gene  replacement  strategies  are  under  investigation.  Progress 
toward clinical gene therapy with mini- and micro-dystrophin 
  constructs   delivered by adeno-associated virus (AAV) has gained 
momentum.1,2  Proof-of-principle  studies  in  the  mdx  mouse 
with micro-dystrophin have demonstrated reversal of the dys-
trophic  process  with  reduced  central  nucleation,  improvement 
in tetanic force measures and increased resistance to eccentric 
contractions.3–5 Gene replacement studies in mdx mice have also 
shown promise in heart6–8 and diaphragm muscle.9–11 In order to 
produce clinically meaningful outcomes of gene transfer, mul-
tiple muscle groups will require transduction. Both arterial and 
venous  approaches  have  demonstrated  success  using  rAAV6, 
rAAV8, and rAAV9 in preclinical studies in mdx mice and canine 
dystrophy.5,11,12 These approaches, although important, fail to rep-
licate some potential obstacles related particularly to dosing and 
anatomical distribution of blood vessels that dominate the clini-
cal environment. These requirements can be addressed, in part, in 
the rhesus macaque where the arteriovenous circulation to muscle 
presents anatomical similarities with DMD boys. In addition, the 
endothelial junctions of capillaries, the interior wall pressures, 
and size ratio of capillaries to muscle fibers more closely simulate 
the clinical setting.
Studies  in  the  nonhuman  primate  (NHP)  and  the  rhesus 
macaque, in particular, offer the opportunity to evaluate a natu-
rally occurring AAV infection by humoral and T-cell immunity to 
this virus. Such conditions potentially more closely simulate clini-
cal gene transfer. In addition, sophisticated tools are evolving to 
characterize the immune response in rhesus macaques through 
the  use  of  major  histocompatibility  complex  haplotyping  and 
tetramer analysis to directly visualize antigen-specific T cells.13
One limitation in the NHP is a biomarker that permits precise 
assessment of vector-mediated gene expression and distribution. 
In this report, we describe the use of a FLAG tag for tracking micro-
dystrophin distribution delivered by AAV8 under control of the 
muscle-specific creatine kinase promoter, MCK. The eight amino-
acid FLAG epitope was originally designed for antibody-mediated 
identification and purification of recombinant proteins.14 FLAG is 
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commonly used to tag proteins for in vitro cell culture assays and 
more recently in vivo when antibodies to a particular antigen are 
not available or are unreliable.14–16 This study represents the first 
time a FLAG epitope tag has been used as a transgene marker to 
differentiate between endogenous and vector-derived protein to 
assess transgene distribution in a NHP. Robust micro-dystrophin.
FLAG expression was documented for at least 5 months with no 
apparent  immunogenicity,  supporting  possible  applicability  for 
other preclinical gene replacement studies relevant to other forms 
of muscular dystrophy.
results
Micro-dys.FlAG gene is highly expressed in mouse 
muscle tissue
The presence of an endogenous dystrophin gene in rhesus macaques 
precludes studying distribution of a traditional micro-dystrophin 
transgene  by  immunohistochemistry.  We  generated  a  human 
micro-dystrophin cassette with an eight amino-acid FLAG pro-
tein tag (micro-dys.FLAG) fused in-frame at the C-terminus. The 
micro-dys.FLAG transgene was driven by the MCK promoter and 
packaged into a rAAV8 vector. A biopotency assay was conducted 
using 4-week-old mdx mice (n = 12) by injecting the tibialis ante-
rior (TA) muscle with 1011 vector genomes (vg) of rAAV8.MCK.
micro-dys.FLAG. Four weeks after gene delivery, 73.2 ± 10.4% of 
muscle fibers in the TA expressed micro-dys.FLAG as determined 
using a FLAG-specific antibody (Figure 1a) and confirmed with 
the N-terminal dystrophin (Dys3) antibody (Figure 1b). Micro-
dystrophin does not stain for C-terminal dystrophin (Dys2).
Micro-dys.FlAG is functional
The value of the micro-dys.FLAG cassette is increased by dem-
onstrating  a  capacity  to  reverse  physiologic  deficits  in  dys-
trophin-deficient  muscle.  We  chose  to  do  these  studies  in  the 
diaphragm  muscle  of  the  mdx  mouse  because  the  severity  of 
the  dystrophic  process  closely  simulates  that  seen  in  patients 
with DMD.17,18 We delivered 2 × 1011 vg (30 µl) of rAAV8.MCK.
micro-dys.FLAG by direct injection to the left ventral quadrant 
of the diaphragm in 8-week-old mdx mice (n = 6). Eight weeks 
after transfer, the diaphragm was isolated, and two muscle strips 
from each mouse (1 mm width) were tested from the targeted area 
of gene transfer for resistance to fatigue (stimulation every sec-
ond for 90   seconds—1 Hz amplitude, 80 ms duration, and 130 ms 
  frequency) and compared to aged-matched mdx and C57/BL10 
controls. Treatment with micro-dys.FLAG significantly protected 
the mdx diaphragm from fatigue (Figure 1c).
Micro-dys.FlAG gene transfer in nHPs
AAV8.MCK.micro-dystrophin.FLAG  was  delivered  to  the  TA 
muscle  of  three  rhesus  macaques  negative  for  AAV8  capsid– 
binding  antibodies  by  enzyme-linked  immunosorbent  assay 
(ELISA) (  subjects: RQ6661, RQ6698, and RQ6706). The left TA 
was  injected  with  5  ×  1012 vg  of  rAAV8.MCK.micro-dys.FLAG 
(three injections ~333 µl each, 0.5 cm apart, and 0.5 cm beneath the 
fascia). The contralateral TA was injected with vector diluent in 
the same manner. These three macaques were prescreened on two 
occasions prior to gene transfer for antigen-specific enzyme-linked 
immuno  sorbent  spot  (ELISpot)  interferon-γ  (IFN-γ)  responses 
directed against AAV8 capsid or micro-dys.FLAG peptide pools. 
Antibody and T-cell responses to the vector and transgene were 
analyzed every 2 weeks following gene transfer for 5 months.
The efficiency of gene transfer was assessed 2 months after 
gene transfer by muscle biopsy from the site of injection via an 
open incision. This time point was chosen because it was well 
beyond the 4-week peak time for rAAV expression in muscle.19,20 
Muscle tissue was sectioned and stained for micro-dys.FLAG and 
examined for immune cell infiltration. Robust gene expression 
(percentage of total muscle fibers expressing micro-dys.FLAG) 
was demonstrated in all three subjects: RQ6661, 50.1%; RQ6698, 
79.1%; RQ6706, 62.3% (Figure 2a,b). Micro-dys.FLAG vg copy 
number  was  also  assessed  in  intramuscular  (IM)-treated  sub-
jects and found to be 2.5 × 106 ± 2.4 × 106 vg/µg genomic DNA 
in treated muscle compared to 0.009 ± 0.009 vg/µg in the contral-
ateral limb (Supplementary Figure S2). Assessment of mononu-
clear cells by counts of CD4+ and CD8+ cells showed no difference 
in the number of cells in the vector versus sham-injected muscle 
(Figure 2c,d).
The three macaques were then killed and necropsied 5 months 
after gene transfer to assess long-term gene expression of micro-
dys.FLAG.  Muscle  was  removed  corresponding  to  the  peri-
  injection site of IM gene injections (the precise target site of gene 
transfer was removed at 2 months). The tissue was blocked, sec-
tioned, and stained for micro-dys.FLAG expression. Robust gene 
expression was demonstrated in all three animals: RQ6661, 37.6 ± 
16.7%; RQ6698, 39 ± 5.4%; RQ6706, 54 ± 17.1% (Figure 3a,b). 
Reduced expression compared to the muscle biopsy at 2 months 
was not unexpected, as this reflects the limited spread of vector 
from the target site of gene transfer. Mononuclear cell infiltra-
tion using specific markers for CD4+ and CD8+ cells showed 
no  difference  between  the  vector  versus  sham-injected  muscle 
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Figure  1  Micro-dystrophin.FlAG  improves  muscle  function. ( a) 
Immuno  staining  with  anti-FLAG  antibody  reveals  robust  micro-
  dystrophin.FLAG  expression  in  mdx  mice.  Inlay:  contralateral  limb 
muscle reveals no FLAG staining. (b) Immunostaining with N-terminal 
dystrophin antibody Dys3 confirms the presence of micro-dystrophin. 
Note:  Dys3  antibody  will  only  recognize  human  N-terminal  dystro-
phin and does not crossreact with mouse dystrophin. Inlay: contralat-
eral limb muscle reveals no dystrophin staining. Bar = 100 µm. (c) mdx 
diaphragms  treated  with  AAV8.MCK.micro-dystrophin.FLAG  are  sig-
nificantly protected from muscle fatigue compared to untreated mdx 
controls (***two-way analysis of variance, P < 0.001), but did not fully 
restore normal function compared to C57/BL10 strain controls.Molecular Therapy  vol. 18 no. 1 jan. 2010  111
© The American Society of Gene & Cell Therapy
Micro-dys.FLAG Delivery in Nonhuman Primates
(Figure 3c,d; Supplementary Figure S1) as was observed in the 
2-month biopsies.
Consistent  with  functional  activity,  the  micro-dys.FLAG 
protein  was  correctly  localized  to  the  sarcolemmal  mem-
brane and colocalized with full-length endogenous dystrophin. 
Immunofluorescent C-terminal dystrophin and anti-FLAG anti-
bodies showed overlapping domains of expression (Figure 4a). 
Western blot analysis confirmed these findings with the N-terminal 
Dys3 dystrophin antibody detecting both the full-length endog-
enous 427 kd dystrophin band and the 138 kd micro-dys.FLAG 
band  in  treated  (T)  samples.  The  micro-dys.FLAG  band  was 
absent in the contralateral control (C) sample confirmed by the 
absence of C-terminal reactivity (Dys2). C-terminal Dys2 reactiv-
ity of the same immunoblot confirmed the endogenous dystro-
phin was full-length (Figure 4b).
Immune responses following direct IM injection
Antigen-specific T cells directed against AAV8 capsid and micro-
dys.FLAG  proteins  were  evaluated  using  overlapping  peptide 
pools encompassing the full-length protein (18-mers   overlapping 
by  11).  Peptides  were  divided  into  three  pools  representing 
N-terminal,  mid,  and  C-terminal  regions  of  the  protein  for 
high-throughput analyses. At 2-week intervals, peripheral blood 
mononuclear cells (PBMCs) were isolated from each animal and 
assayed for IFN-γ ELISpot responses to transgene and capsid. A 
positive response is defined as ≥50 spot-forming colonies per 106 
PBMCs.
No micro-dys.FLAG T-cell response was detected above back-
ground in any animal at any time point. In similar fashion, there 
was virtually no detectable capsid-specific T-cell response, except 
for  two  transient,  marginally  positive  responses  to  the  AAV8 
capsid pool 3 at 14 days after gene transfer in animal RQ6661 and 
at day 42 in animal RQ6698 (82 and 77 spot-forming colonies/
million PBMCs, respectively) (Figure 5).
Anti-AAV-binding  antibodies  to  the  AAV8  capsid  were 
detected in all animals as early as 2 weeks after gene transfer 
(Figure 5b) confirming delivery of an immunogenic capsid dose 
to all three animals.
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Figure 2  two-month muscle biopsy reveals widespread micro-dys.FlAG expression. (a) A biopsy of all three primates from the site of gene 
transfer revealed robust staining of micro-dystrophin FLAG localized to the sarcolemmal membrane compared to no staining in contralateral control 
(a′). Bar = 400 µm for montage and 200 µm for ×20 images. (b) Percentage of micro-dys.FLAG transduced muscle fibers from each biopsy. (c,d) 
Quantitative comparison of CD4 and CD8 T cells present in the biopsy of treated muscle versus the contralateral limb muscle. Error bars, standard 
deviation. Student’s t-test was used to determine significance between sides (P > 0.05).112  www.moleculartherapy.org  vol. 18 no. 1 jan. 2010     
© The American Society of Gene & Cell Therapy
Micro-dys.FLAG Delivery in Nonhuman Primates
targeted vascular delivery of micro-dystrophin 
to gastrocnemius muscle
The NHP provides a testing paradigm for vascular delivery trans-
lational studies due to anatomic parallels with humans. Mirroring 
a potential clinical protocol, anti-AAV8 serostatus was determined 
for four rhesus macaques. Four animals were identified: two were 
negative (subjects: 01D299 and RQ6539) and two were positive 
(subjects: 03E101 and 03E062) for pre-existing AAV8 antibodies. 
Two baseline bleeds were performed to collect PBMCs for serial 
IFN-γ ELISpot analysis of capsid and transgene along with serum 
for AAV8 antibody–binding ELISAs. These analyses were repeated 
at 2-week intervals throughout the study.
The left hindlimb of four rhesus macaques (4–8 kg animals) 
was perfused with 2 × 1012 vg/kg rAAV8.MCK.micro-dys.FLAG 
in  2.5 ml/kg  saline,  through  a  catheter  advanced  to  the  sural 
artery, which is the arterial supply for the gastrocnemius muscle. 
This muscle was chosen as a proof of principle that vector could 
be specifically targeted by vascular delivery. Specific needs will 
dictate the muscle groups to be targeted in a clinical trial. Two 
tourniquets were used to compartmentalize delivery, one above 
the knee ~0.5 inches above the catheter tip and a second above 
the ankle. A preflush (2.5 ml/kg over 60 seconds) of sterile saline 
was given with the proximal tourniquet occluding flow to mini-
mize arterial blood supplying the gastrocnemius. After occluding 
flow completely with both tourniquets, the vector was delivered 
over 60 seconds followed by a 10-minute dwell time. A postflush 
(2.5 ml/  kg  over  60  seconds)  was  delivered  immediately  before 
removing the tourniquet. None of the animals suffered noticeable 
edema or adverse effects from the procedure.
Three months after transfer, the macaques were euthanized, 
and  the  gastrocnemius  muscle  was  removed,  cut  into  blocks 
(~1.0 × 0.75 cm), and snap-frozen. Micro-dystrophin expression 
was  visualized  by  immunofluorescence  using  an  anti-FLAG 
  antibody. All four monkeys had efficient transduction of the gas-
trocnemius muscle (Figure 6a; Table  1), with subjects 01D299 
and RQ6539 (those without pre-existing AAV8 antibodies) dem-
onstrating 82 and 89% transduction, respectively in the central 
portion of the muscle, and subjects 03E101 and 03E062 (those 
with pre-existing AAV8 antibodies) demonstrating 39 and 35% 
transduction, respectively. Expression levels were also confirmed 
with quantitative PCR in subjects treated by isolated limb perfu-
sion. Micro-dys.FLAG vg copy number was assessed and found 
to be 2.2 × 105 ± 1.7 × 105 vg/µg genomic DNA in treated muscle 
from subjects 01D299 and RQ6539 (without pre-existing AAV8 
antibodies) compared to 2.8 × 103 ± 1.3 × 103 vg/µg in subjects 
03E101 and 03E062 (those with pre-existing AAV8 antibodies) 
(Supplementary Figure S2). Histological assessment in all sam-
ples with gene expression revealed no inflammation, necrosis, or 
change in morphology (Figure 6b).
Immune responses following vascular delivery
Antigen-specific T-cell responses were monitored every 2 weeks 
over  the  course  of  the  study  using  PBMCs.  There  were  no 
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Figure 3  Persistent expression micro-dys.FlAG at 5 months. (a) Excision of the entire gene transfer site revealed sustained expression in all three 
primates. Bar = 200 µm. (a′) Contralateral control shows no FLAG staining. (b) Mean percentage of micro-dys.FLAG transduced muscle fibers from 
tissue blocks (six blocks each, ~0.5 × 0.5 × 0.5 cm) harvested from injection site for each subject (error bars ± SD). (c,d) Quantitative comparison of 
CD4 and CD8 T cells present in the biopsy tissue versus the contralateral muscle (error bars ± SD). Student’s t-test was used to determine significance 
between sides (P > 0.05).
table 1  Micro-dystrophin percent transduction following vascular 
delivery
subject
Gastrocnemius
Proximal central distal
01D299 70.3 ± 13.9 81.6 ± 5.2 64 ± 10.4
RQ6539 78 ± 14.3 88.5 ± 4.8 65 ± 10.6
03E101 31 ± 6.0 39 ± 8.5 29 ± 7.6
03E062 27 ± 10.0 35 ± 9.8 30 ± 12.2
Data are presented as mean ± SEM.Molecular Therapy  vol. 18 no. 1 jan. 2010  113
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significant IFN-γ responses to capsid or transgene peptide pools 
up to and including the day of necropsy 3 months after gene trans-
fer (Figure 6c). To eliminate the possibility that a T-cell response 
could be occurring in the muscle at a level below the threshold of 
detection in the peripheral blood, T cells were directly isolated 
from necropsied muscle tissue. No IFN-γ ELISpot response to 
capsid  or  micro-dys.FLAG  was  observed  using  these  muscle-
derived  T  cells.  Moreover,  clonal  expansion  and  restimulation 
with  micro-dys.FLAG  and  capsid  peptide  pools  also  failed  to 
elicit a positive response, further confirming our findings that 
AAV8.micro-dys.FLAG  was  not  immunogenic  when  delivered 
by a vascular route. These data demonstrate that rAAV8 is effi-
cient at transducing the underlying musculature of the primate 
host in the presence of anti-AAV antibodies and without eliciting 
a T-cell immune response to vector or transgene that could pre-
clude expression. FLAG-tagged micro-dystrophin was also shown 
to correctly localize to the muscle sarcolemma and persist for at 
least 3–5 months without apparent diminution.
dIscussIon
Demonstration  of  persistent  FLAG-tagged  human  micro-
  dystrophin  expression  in  a  NHP  has  significant  advantages  in 
facilitating  the  goal  of  intravascular  delivery  for  human  gene 
therapy trials in DMD. In the NHP studies, the intravascular sites 
of delivery provide anatomical thoroughfares for muscle-specific 
targeting and offer information on viral dosing to achieve robust 
levels of muscle transduction that are well within those expected 
to   represent a therapeutic range.21 We demonstrated sustained 
micro-dystrophin.FLAG expression for at least 3–5 months by 
either IM or intravascular routes without overt T-cell immune 
responses to vector capsid or the micro-dys.FLAG transgene. The 
vascular delivery method detailed herein is clinically applicable 
for targeted delivery in terms of vector dose, volume of admin-
istration,  intra-arterial  pressure,  and  catheterization  technique. 
The studies therefore represent a useful preclinical paradigm to 
continue to test vascular delivery to specific muscle groups with 
implications  for  whole  limb  delivery.  Micro-dystrophin.FLAG 
correctly localized to the sarcolemmal membrane in the presence 
of endogenous dystrophin allowing accurate assessment of the 
delivery technique and percentage of muscle fibers transduced.
As a nonhuman serotype, AAV8 may have particular advan-
tages for clinical gene therapy by permitting evasion of pre-  existing 
AAV2  natural  immunity  and  reduced  antigen-presenting  cell 
transduction in the human host.22–24 All animals (whether naive 
or AAV antibody positive) rapidly seroconverted following vector 
administration by either route, which may preclude vector admin-
istration. However, transgene expression was observed following 
vascular delivery to two AAV8 positive animals, which suggests 
that gene transfer is possible in seropositive animals. Although 
these data are encouraging, naive animals without pre-existing 
AAV8  antibody  demonstrated  approximately  twofold  higher 
expression than animals with pre-existing antibodies, implying 
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that such antibodies partially block transduction as observed in 
other models.23
The use of an eight amino-acid FLAG epitope tag fused to the 
C-terminus of micro-dystrophin allowed for assessment of trans-
gene distribution in the presence of endogenous macaque dystro-
phin. Detection of the FLAG epitope was critical for the success of 
the study to accurately assess vascular distribution. FLAG did not 
elicit a T-cell immune response as measured by IFN-γ ELISpot 
induction and thus represents an ideal strategy to tag proteins also 
expressed endogenously.
The findings in this NHP study have implications for other 
muscle diseases as well. The recently reported success in type 2D 
limb-girdle muscular dystrophy IM α-sarcoglycan (SGCA) clini-
cal gene transfer by an AAV vector bodes well for vascular delivery 
in this form of dystrophy.25 Labeling SGCA with a FLAG-tag and 
performing vascular delivery studies such as the one described 
herein should expedite translation to the clinic.
MAterIAls And MetHods
Micro-dystrophin gene construction. The human micro-dystrophin cas-
sette contained the (R4–R23/Δ71–78) domains as previously described, 
and the FLAG epitope (DYKDDDDK) was added to the C-terminus as a 
translational fusion by PCR.3 The complementary DNA was codon opti-
mized for human usage and synthesized by GenScript (Piscataway, NJ). 
It includes a consensus Kozak sequence, an SV40 intron, and synthetic 
polyadenylation site (53 base pairs). A muscle creatine kinase promoter/
enhancer was used to drive muscle-specific gene expression. The MCK 
micro-dystrophin.FLAG expression cassette was cloned between AAV2 
inverted terminal repeats using flanking XbaI restriction enzyme sites in 
a plasmid derived from pCMVβ (Clontech, Mountain View, CA). MscI/
SmaI restriction enzyme digestions were used to confirm ITR integrity.
rAAV  vector  production.  rAAV  vectors  were  produced  by  a  modified 
cross-packaging approach whereby the AAV type 2 ITRs can be packaged 
into multiple AAV capsid serotypes.26 Production was accomplished using 
a standard 3 plasmid DNA CaPO4 precipitation method using HEK293 
cells. Two hundred ninety-three cells were maintained in Dulbecco’s modi-
fied Eagle’s medium supplemented with 10% fetal bovine serum, penicil-
lin, and streptomycin. The production plasmids were as follows: (i) pAAV.
MCK.microdys.FLAG,  (ii)  rep2-cap8  modified  AAV  helper  plasmids 
encoding cap serotype 8-like isolate rh.74, and (iii) an adenovirus type 5 
helper plasmid (pAdhelper) expressing adenovirus E2A, E4 ORF6, and VA 
I/II RNA genes. A quantitative PCR-based titration method was used to 
determine an encapsidated vg titer utilizing a Prism 7500 TaqMan detec-
tor system (PE Applied Biosystems, Foster City, CA).27 The primer and 
fluorescent probe targeted the MCK promoter and were as follows: MCK 
forward  primer,  5-CCCGAGATGCCTGGTTATAATT-3;  MCK  reverse 
primer,  5-GCTCAGGCA  CAGGTGTTG-3;  and  MCK  probe,  5-FAM-
CCAGACATGTGGCTGCTCCCCC-TAMRA-3.
Animals and treatments
IM injection of the TA of mouse: All procedures were approved by the 
Research Institute at Nationwide Children’s Hospital Institutional Animal 
Care and Use Committee. Three to four-week-old mdx mice and normal age-
matched C57/BL10 were used for IM injection. Mice were anesthetized and 
maintained on 1–4% Isoflurane (in oxygen). Both hindlimbs were shaved, 
and the TA muscle was injected with 3 × 1010 vg of rAAV8.micro-dystrophin.
FLAG or normal saline (30 μl volume) using a 30-gauge insulin syringe.
IM injection of the diaphragm of mouse: Briefly, mice were weighed and 
anesthetized with a combination of ketamine and xylazine (100 mg/  kg and 
10 mg/kg, respectively). A single abdominal incision was made from the base 
of the sternum to just above the pelvis (~1 cm incision). The diaphragm was 
identified, and 30 µl of the vector preparation in sterile saline was delivered 
using a 32-gauge needle. The abdominal wall was closed with 4.0 Vicryl 
Plus continuous sutures, and skin wound was closed with sterile surgical 
staples.  Mice  were  treated  with  a  postoperative  dose  of  buprenorphine 
0.01 mg/  kg subcutaneously for pain. The animals are allowed to recover on 
a 37 °C warmer.
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Figure 5  cellular immune response. (a) Enzyme-linked immunosor-
bent spot assay for detection of transgene and/or capsid-specific T cells 
in PBMCs by interferon-γ secretion. Fifty reactive spots per million cells 
(dotted line) represent the threshold for a significant response. Black 
arrow indicates the time of biopsy. The only marginally positive responses 
to be noted were at day 14 for RQ6661 and day 42 for RQ6698. These 
were not sustained and had no influence on gene expression. (b) AAV8 
binding Ab titers. Antibodies to AAV8 capsid in serum were quantified 
by enzyme-linked immunosorbent assay and monitored every 2 weeks. 
AAV8 Ab ratio = ratio OD with AAV8 coat/without AAV8 coat. All three 
animals demonstrated rapid seroconversion in AAV8 Abs after immuni-
zation with rAAV8.MCK.micro-dys.FLAG. Ab, antibody; HBV, hepatitis B 
virus; OD, optical density; PBMC, peripheral blood mononuclear cell; 
SFC, spot-forming colonies.Molecular Therapy  vol. 18 no. 1 jan. 2010  115
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Diaphragm fatigue protocol in mouse: Mice were euthanized, and 
the diaphragm dissected with rib attachments and central tendon intact, 
and placed in K-H buffer (5 mmol/l KCl, 137 mmol/l NaCl, 1.2 mmol/l 
NaH2PO4-H2O, and 1.2 mmol/l MgSO4). A 1 mm wide section (from rib 
to tendon) of diaphragm was isolated and attached to a force transducer. 
The diaphragm strip was looped around a basket assembly attached to 
the transducer (the rib cartilage serves as the anchor), and the tendon 
was pierced by a pin. The muscle was stretched to optimal length (length 
at maximum twitch force) for measurement of twitch contractions and 
rested for 5 minutes before starting the muscle fatigue protocol. The muscle 
fatigue protocol measured the force exerted by the muscle when stimulated 
every second for 90 seconds (1 Hz amplitude, 80 ms duration, and 130 ms 
frequency). Following the muscle fatigue protocol, the muscle strip was 
removed from the apparatus, the rib cartilage removed and weighed.
NHP IM injection: Three 7-year-old Chinese rhesus macaques that 
did not possess AAV8-binding antibodies above background were studied 
(ELISA performed using 1:50 serum dilution). All NHPs were housed in 
pairs to promote socialization. The macaques were anesthetized using 
Telazol (5 mg/kg IM) and treated with buprenorphine (0.01 mg/kg) IM 
preoperatively. The TA of both hindlimbs was shaved and prepared with 
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Figure 6  targeted vascular delivery of micro-dystrophin.FlAG in nonhuman primates. (a) The targeted gastrocnemius muscle from all four pri-
mates revealed robust staining of micro-dystrophin.FLAG localized to the sarcolemmal membrane at 3 months after gene transfer. Bar = 200 µm, ×10 
images. (a′) Contralateral control shows no FLAG staining. (b) Hematoxylin and eosin staining from isolated muscle tissue at the site of gene trans-
fer revealed no evidence of tissue damage or cellular infiltration. (c) Enzyme-linked immunosorbent spot assay for detection of transgene and/or 
capsid-specific T cells in PBMCs. Pool 1 is composed of aa14-240 (actin-binding domain), aa253-327 (hinge 1), and aa337-427 (first part of spectrin 
repeat 1). Pool 2 is composed of aa428-447 (remainder of spectrin repeat 1), aa448-556 (spectrin repeat 2), aa557-667 (spectrin repeat 3), aa668-
717 (hinge 2), and aa2932-3040 (spectrin repeat 24). Pool 3 is composed of aa3041-3112 (hinge 4), aa3080-3360 (cysteine repeat region), plus 
the sequence of the FLAG tag. Two marginally positive responses against micro-dys pool 3 in animal 03E101 were noted at days 15 and 71. These 
responses were not sustained and had no influence on long-term gene expression. HBV, hepatitis B virus; PBMC, peripheral blood mononuclear cell; 
SFC, spot-forming colonies.116  www.moleculartherapy.org  vol. 18 no. 1 jan. 2010     
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95% EtOH and povidone solution, and the animal secured to a warming 
blanket (37 °C) that overlies the surgery table. The TA was visualized by 
blunt dissection, and 5 × 1012 vg of rAAV8.micro-dystrophin.FLAG or 
normal saline (1 ml volume total) was injected in three sites 0.5 cm apart. 
The fascial layer and skin incision were closed with 3–4 interrupted Vicryl 
sutures and skin bond, and the injection site was marked with tattoo ink. 
For the muscle biopsy at 8 weeks, an incision was made to visually expose 
the TA muscle, using sterile drapes and scalpels. A small muscle biopsy 
was obtained (block 0.75–1.0 × 0.5 cm), with bleeding controlled by direct 
pressure. The wound was closed with interrupted Vicryl sutures.
Isolated  limb  perfusion  in  rhesus  macaques:  Rhesus  macaques 
were sedated with IM Telazol (3–6 mg/kg), intubated and secured to a 
heated procedure table at 37 °C. General anesthesia was administered 
with Isoflurane (in oxygen) 1–4% during the procedure. The left groin 
was shaved with extension to the mid thigh, and prepped with povidone–
iodine solution followed by 95% ethanol. A groin incision was made over 
the femoral bundle, and the femoral artery was isolated. The femoral 
artery was catheterized using fluoroscopy-guided 3-0 f catheter (Cook) 
that was advanced to the sural branch of the popliteal artery. Prior to 
vector administration, a prevector flush of saline (2.5 ml/kg) was given 
over 1 minute. This was immediately followed by occluding blood flow to 
the extremity using a standard phlebotomy tourniquet placed proximal to 
the tip of the catheter that was typically right above the knee. A second 
tourniquet was placed at the base of the gastrocnemius. rAAV8.MCK.
micro-dys.FLAG was infused over 60 seconds at a dose of 2 × 1012 vg/kg 
in 2.5 ml/kg of Tris buffered saline. The extremity remained isolated from 
the circulation for 10 minutes. A postvector flush (2.5 ml/kg) was infused 
over 1 minute and then the tourniquets were released. Direct pressure 
was applied for 10 minutes to control bleeding, and the wound was closed 
with 4-0 Vicryl suture.
Gene expression analyses. TA and gastrocnemius skeletal muscles were col-
lected from treated and contralateral control limbs at 8 weeks and 5 months 
after treatment, respectively, for subjects treated by IM injection. A single 
1.0 × 0.5 cm block was removed at biopsy at the 8-week time point, and the 
remainder of the TA was removed and blocked at necropsy at 5 months. 
Subjects treated by isolated limb perfusion were killed at 3 months at which 
time the entire gastrocnemius muscle was removed and blocked (0.75–1.0 × 
0.5 cm blocks). Muscles were embedded in 7% gum tragacanth and flash-
frozen in isopentane cooled in liquid nitrogen. Cryostat sections (12 µm) 
for FLAG immunofluorescence were incubated with anti-FLAG polyclonal 
primary antibody (F7425; Sigma, St Louis, MO) at a dilution of 1:175 in 
blocking buffer [phosphate-buffered saline (PBS), 10% goat serum, 0.1% 
Triton X-100] for 1 hour at 25 °C in a wet chamber. For dystrophin-specific 
staining, Dys2 (NCL-Dys2; Novocastra Laboratories, Newcastle, UK) pri-
mary antibody was used (1:3 in blocking buffer). Sections were then washed 
with PBS three times, each for 20 minutes and reblocked. Visualization was 
achieved by incubation for 45 minutes at 25 °C with an Alexa 568 goat anti-
rabbit or Alexa 488-conjugated IgG1 isotype-specific goat anti-mouse anti-
body at a 1:300 dilution (Molecular Probes, Carlsbad, CA). Sections were 
washed with PBS three times for 20 minutes and mounted with Vectashield 
mounting medium (Vector Laboratories, Burlingame, CA). Fluorescence 
staining was visualized using a Zeiss Axioskop 2 Plus Microscope (Zeiss, 
Thornwood, NY), and images were captured with a Zeiss AxioCam MRC5 
camera  (Zeiss).  The  number  of  fibers  with  sarcolemmal  staining  were 
expressed as percentage of all fibers. Means for IM necropsy studies were 
obtained from the mean of six blocks surrounding the original injection 
site. Means for isolated limb perfusion studies were obtained by count-
ing four ×10 fields from six muscle blocks in proximal, central, and distal 
regions for each muscle.
Western blot analysis. Tissue sections (10–20 μm thick) from micro-dys.
FLAG treated and untreated muscle were collected into a microcentrifuge 
tube and homogenized with 100 μl homogenization buffer (125 mmol/l 
Tris-HCl, pH 6.8, 4% sodium dodecyl sulfate, 4 mol/l urea, 5% βME and 
protease inhibitor cocktail). Protein levels were quantified using RC/DC 
method  (BioRad  Laboratories,  Hercules,  CA).  Protein  samples  (50 μg 
per lane) were electrophoresed on a 3–8% polyacrylamide Tris-Acetate 
gel (NuPAGE; Invitrogen, Carlsbad, CA) and then transferred to a poly-
vinylidene fluoride membrane (Amersham Biosciences, Pittsburgh, PA). 
After blocking for 1 hour in 5% nonfat dry milk in TBST (100 mmol/l 
Tris-HCl, pH 8.0, 167 mmol/l NaCl, 0.1% Tween), the western blot was 
incubated  overnight  with  dystrophin  monoclonal  antibody  NCL-DYS2 
or DYS3 (Novocastra Laboratories) at a dilution of 1:100, followed by 
horseradish  peroxidase–labeled  goat  anti-mouse  IgG  (GE  Healthcare, 
Piscataway, NJ) at a dilution of 1:2,000 for 1 hour. Immunoreactive bands 
were visualized with the use of the ECL Plus western blotting detection sys-
tem (GE Healthcare) and Hyperfilm ECL (Amersham Biosciences). Signal 
intensities were measured with ImageQuant software (GE Healthcare).
Quantitative PCR to detect genome copy number. TaqMan quantitative 
PCR was used to quantify the number of vg copies compared to contral-
ateral  control  tissue  as  described.27  A  vector-specific  primer  probe  set 
amplified a portion of the unique sequence of the MCK promoter within 
the micro-dystrophin.FLAG cassette. The rhesus erythropoietin gene was 
used as an internal control to normalize for genomic input and confirm the 
absence of PCR inhibitors in the sample DNA. Copy number is reported as 
vg per microgram of genomic DNA.
Mononuclear  cell  analysis.  Immunohistochemistry  was  performed  to 
identify immune cells. Tissue sections were incubated with monoclonal 
antibodies to CD4 (L200; BD Biosciences, San Jose, CA), CD8 (RPA-T8; 
BD  Biosciences)  and  were  diluted  1:50  with  PBS.  Visualization  was 
achieved with DAB substrate using the Super Sensitive Polymer-HRP IHC 
Detection System for Automation (QD410-YAX; BioGenex, San Ramon, 
CA). The entire muscle section was analyzed, and the number of mononu-
clear cells were counted and expressed as total number per mm2.
IFN-γ ELISpot analysis. ELISpot assays were performed on fresh PBMCs, 
which were added at a concentration of 2 × 105/well in duplicate wells of 
a 96-well flat-bottom membrane plate (Millipore, Billerica, MA). Three 
peptide pools were used for the AAV8 capsid protein (Genemed Synthesis, 
San Antonio, TX), containing 34–36 peptides, each 18 amino-acid long 
and overlapping by 11 residues. Three peptide pools encompassed the 
micro-dystrophin.FLAG  protein  (Genemed  Synthesis)  and  contained 
36–42 peptides, each 20 amino-acid long and overlapping by 10 residues. 
The final two peptides of the micro-dystrophin.FLAG pool 3 were specific 
for the FLAG-tag epitope. Pool 1 is composed of aa14-240 (actin-bind-
ing domain), aa253-327 (hinge 1), and aa337-427 (first part of spectrin 
repeat 1). Pool 2 is composed of aa428-447 (remainder of spectrin repeat 
1), aa448-556 (spectrin repeat 2), aa557-667 (spectrin repeat 3), aa668-
717 (hinge 2), and aa2932-3040 (spectrin repeat 24). Pool 3 is composed 
of aa3041-3112 (hinge 4), aa3080-3360 (cysteine repeat region), plus the 
sequence of the FLAG-tag. Concanavalin A (Sigma) served as a positive 
control and a hepatitis B virus peptide pool as a negative control. Peptides 
were added directly to the wells at a final concentration of 1 µg/ml in 
200 µl of AIM-HS [Aim-V lymphocyte media (Invitrogen) supplemented 
with  2%  human  AB  serum  (Gemini-BioScience,  Basel,  Switzerland)]. 
Monkey IFN-γ ELISpot kits were purchased from U-CyTech (Utrecht, the 
Netherlands). After the addition of PBMCs and peptides, the plates were 
incubated at 37 °C for 48 hours and then developed according to the man-
ufacturer’s protocol. IFN-γ spot formation was counted using a Cellular 
Technologies systems analyzer (Cellular Technologies, Cleveland, OH).
ELISA analysis. An ELISA was performed to measure the level of circulat-
ing AAV8 capsid–binding antibody in serum. Immulon-4 96-well plates 
(ISC BioExpress, Kaysville, UT) were coated with 100 µl of 2 × 1010 vg/ml 
AAV8 viral stock in carbonate buffer (pH 9.4; Pierce, Rockford, IL) per Molecular Therapy  vol. 18 no. 1 jan. 2010  117
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well. Plates were sealed overnight at 4 °C. Plates were blocked with 280 µl 
per well of a 5% nonfat dry milk and 1% normal goat serum (Invitrogen) 
in PBS for 3 hours at 25 °C. Rhesus plasma was diluted at a 1:50 ratio in 
solution identical to the   blocking   solution, and 100 µl added in duplicate 
to both wells coated with AAV8 particles in carbonate buffer and wells 
coated with carbonate buffer alone. Plates were incubated at 25 °C for 1 
hour before being washed five times with 280 µl of PBS-T (0.05% Tween). 
Blocking solution was used again to dilute the secondary antibody, goat 
anti-monkey  IgG-HRP  (Sigma)  at  a  1:10,000  dilution.  Wells  received 
250 µl of the secondary antibody and were incubated at 25 °C for 30 min-
utes before being washed five times and blotted dry. Tetramethylbenzidine 
(100 µl/well; Pierce) was added and incubated at 25 °C for 10 minutes in 
the dark, before the addition of 100 µl of 1N H2SO4 (Acros Organics, Geel, 
Belgium) to stop the reaction. The OD450 was measured using a Wallace 
1420-050 Multilabel Counter (PerkinElmer, Waltham, MA). Samples were 
considered positive if the OD450 average of the antigen-coated wells was 
three times greater than wells coated with carbonate buffer alone.
suPPleMentArY MAterIAl
Figure  S1. Micro-dystrophin.FLAG  gene  transfer  does  not  induce 
  histopathological changes.
Figure S2. Vector genome copy number.
AcKnoWledGMents
We thank the Viral Vector Core at Nationwide Children’s Hospital for 
vector  production.  Research  supported  by  the  Children’s  Hospital 
Foundation (J.R.M.); National Institutes of Health U54 (1U54NS055958-
01A1) to J.R.M., L.G.C., K.R.C., Z.S., and C.M.W.; Muscular Dystrophy 
Association to J.R.M.; Jesse’s Journey Foundation for Gene and Cell 
Therapy, Ruth L. Kirschstein National Research Service Award postdoc-
toral fellowship (1F32AR055008) to L.R.R.-K.
reFerences
1.  Rodino-Klapac, LR, Chicoine, LG, Kaspar, BK and Mendell, JR (2007). Gene therapy 
for duchenne muscular dystrophy: expectations and challenges. Arch Neurol 64: 
1236–1241.
2.  Wang, Z, Chamberlain, JS, Tapscott, SJ and Storb, R (2009). Gene therapy in large 
animal models of muscular dystrophy. ILAR J 50: 187–198.
3.  Harper, SQ, Hauser, MA, DelloRusso, C, Duan, D, Crawford, RW, Phelps, SF et al. 
(2002). Modular flexibility of dystrophin: implications for gene therapy of Duchenne 
muscular dystrophy. Nat Med 8: 253–261.
4.  Liu, M, Yue, Y, Harper, SQ, Grange, RW, Chamberlain, JS and Duan, D (2005). 
Adeno-associated virus-mediated microdystrophin expression protects young mdx 
muscle from contraction-induced injury. Mol Ther 11: 245–256.
5.  Rodino-Klapac, LR, Janssen, PM, Montgomery, CL, Coley, BD, Chicoine, LG, Clark, KR 
et al. (2007). A translational approach for limb vascular delivery of the micro-
dystrophin gene without high volume or high pressure for treatment of Duchenne 
muscular dystrophy. J Transl Med 5: 45.
6.  Bostick, B, Yue, Y, Lai, Y, Long, C, Li, D and Duan, D (2008). Adeno-associated 
virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic 
abnormalities in mdx mice. Hum Gene Ther 19: 851–856.
7.  Bostick, B, Yue, Y, Long, C, Marschalk, N, Fine, DM, Chen, J et al. (2009). Cardiac 
expression of a mini-dystrophin that normalizes skeletal muscle force only partially 
restores heart function in aged Mdx mice. Mol Ther 17: 253–261.
8.  Townsend, D, Blankinship, MJ, Allen, JM, Gregorevic, P, Chamberlain, JS and 
Metzger, JM (2007). Systemic administration of micro-dystrophin restores cardiac 
geometry and prevents dobutamine-induced cardiac pump failure. Mol Ther 15: 
1086–1092.
9.  Blankinship, MJ, Gregorevic, P, Allen, JM, Harper, SQ, Harper, H, Halbert, CL et al. 
(2004). Efficient transduction of skeletal muscle using vectors based on adeno-
associated virus serotype 6. Mol Ther 10: 671–678.
10.  Mah, C, Fraites, TJ Jr, Cresawn, KO, Zolotukhin, I, Lewis, MA and Byrne, BJ (2004). 
A new method for recombinant adeno-associated virus vector delivery to murine 
diaphragm. Mol Ther 9: 458–463.
11.  Gregorevic, P, Allen, JM, Minami, E, Blankinship, MJ, Haraguchi, M, Meuse, L et al. 
(2006). rAAV6-microdystrophin preserves muscle function and extends lifespan in 
severely dystrophic mice. Nat Med 12: 787–789.
12.  Yue, Y, Ghosh, A, Long, C, Bostick, B, Smith, BF, Kornegay, JN et al. (2008). A single 
intravenous injection of adeno-associated virus serotype-9 leads to whole body 
skeletal muscle transduction in dogs. Mol Ther 16: 1944–1952.
13.  Wherry, EJ, Barber, DL, Kaech, SM, Blattman, JN and Ahmed, R (2004). Antigen-
independent memory CD8 T cells do not develop during chronic viral infection. 
Proc Natl Acad Sci USA 101: 16004–16009.
14.  Hopp, TP, Prickett, KS, Price, VL, Libby, RT, March, CJ, Cerretti, DP et al. (1988). 
A short polypeptide marker sequence useful for recombinant protein identification 
and purification. Biotechnology (N Y) 6: 1204–1210.
15.  Louboutin, JP, Reyes, BA, Agrawal, L, Van Bockstaele, E and Strayer, DS (2007). 
Strategies for CNS-directed gene delivery: in vivo gene transfer to the brain using 
SV40-derived vectors. Gene Ther 14: 939–949.
16.  Terpe, K (2003). Overview of tag protein fusions: from molecular and biochemical 
fundamentals to commercial systems. Appl Microbiol Biotechnol 60: 523–533.
17.  Ishizaki, M, Suga, T, Kimura, E, Shiota, T, Kawano, R, Uchida, Y et al. (2008). Mdx 
respiratory impairment following fibrosis of the diaphragm. Neuromuscul Disord 18: 
342–348.
18.  Stedman, HH, Sweeney, HL, Shrager, JB, Maguire, HC, Panettieri, RA, Petrof, B 
et al. (1991). The mdx mouse diaphragm reproduces the degenerative changes of 
Duchenne muscular dystrophy. Nature 352: 536–539.
19.  Fisher, KJ, Jooss, K, Alston, J, Yang, Y, Haecker, SE, High, K et al. (1997). 
Recombinant adeno-associated virus for muscle directed gene therapy.  
Nat Med 3: 306–312.
20.  Kessler, PD, Podsakoff, GM, Chen, X, McQuiston, SA, Colosi, PC, Matelis, LA 
et al. (1996). Gene delivery to skeletal muscle results in sustained expression 
and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA 93:  
14082–14087.
21.  Corrado, K, Rafael, JA, Mills, PL, Cole, NM, Faulkner, JA, Wang, K et al. (1996). 
Transgenic mdx mice expressing dystrophin with a deletion in the actin-binding 
domain display a “mild Becker” phenotype. J Cell Biol 134: 873–884.
22.  Gao, GP, Alvira, MR, Wang, L, Calcedo, R, Johnston, J and Wilson, JM (2002). Novel 
adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. 
Proc Natl Acad Sci USA 99: 11854–11859.
23.  Li, H, Lin, SW, Giles-Davis, W, Li, Y, Zhou, D, Xiang, ZQ et al. (2009). A preclinical 
animal model to assess the effect of pre-existing immunity on AAV-mediated gene 
transfer. Mol Ther 17: 1215–1224.
24.  Li, H, Murphy, SL, Giles-Davis, W, Edmonson, S, Xiang, Z, Li, Y et al. (2007). 
Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate  
AAV-transduced hepatocytes. Mol Ther 15: 792–800.
25.  Mendell, JR, Rodino-Klapac, LR, Rosales-Quintero, X, Kota, J, Coley, BD, Galloway, G 
et al. (2009). Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-
sarcoglycan and associated proteins. Ann Neurol 66: 290–297.
26.  Rabinowitz, JE, Rolling, F, Li, C, Conrath, H, Xiao, W, Xiao, X et al. (2002). 
Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome 
into multiple AAV serotypes enables transduction with broad specificity. J Virol 76: 
791–801.
27.  Clark, KR, Liu, X, McGrath, JP and Johnson, PR (1999). Highly purified recombinant 
adeno-associated virus vectors are biologically active and free of detectable helper 
and wild-type viruses. Hum Gene Ther 10: 1031–1039.